Specialist Scientist, SAMRC, South Africa.
Hygon Mutavhatsindi is a Specialist Scientist at the South African Medical Research Council (SAMRC) with a robust background in biochemistry, molecular biology, and immunology. His research explores infectious diseases, particularly tuberculosis (TB), HIV, and COVID-19, using molecular and immunological techniques. Dr. Mutavhatsindi has made significant contributions to immunology and TB research, aiming to identify non-sputum biomarkers to improve TB diagnosis and treatment outcomes. His work has earned him national and international recognition, alongside numerous grants and awards.
Profile
Scopus
Orcid
Education 🎓
Dr. Hygon Mutavhatsindi began his academic journey at the University of Venda, where he earned a BSc in Biochemistry and Biology (2009-2012), followed by an Honours degree in Biochemistry in 2013. He continued to pursue advanced studies at the same institution, obtaining an MSc in Biochemistry (2014-2015). His passion for molecular biology led him to Stellenbosch University, where he completed his PhD in Molecular Biology (2016-2019). During his doctoral studies, Dr. Mutavhatsindi focused on cutting-edge research, contributing to scientific advancements in his field.
Following his PhD, Dr. Mutavhatsindi undertook a prestigious Postdoctoral Fellowship in Immunology at the University of Cape Town (2020-2023). During this period, he deepened his expertise in immunological research, working on projects that explored the intricate mechanisms of immune response. His postdoctoral work not only advanced his academic credentials but also positioned him at the forefront of immunological science, further strengthening his research profile and contributing to ongoing scientific discussions in molecular biology and immunology.
Experience 💼
Dr. Hygon Mutavhatsindi currently serves as a Specialist Scientist at the South African Medical Research Council (SAMRC), a role he began in February 2024. In this position, he leads research efforts in tuberculosis (TB) and immunology, supervises postgraduate students, and manages multiple research projects. Prior to this, he was a Scientific Officer at the Cape Town HVTN Immunology Laboratory (May 2023–January 2024), where he conducted clinical studies and flow cytometry experiments, contributing to crucial immunological research.
Before taking on these roles, Dr. Mutavhatsindi completed a Postdoctoral Research Fellowship at the University of Cape Town (February 2020–January 2023), where his work focused on TB and COVID-19 immunology. His academic journey began as a PhD Researcher at Stellenbosch University (June 2016–December 2019), where he specialized in identifying TB biomarkers and evaluating treatment responses, building a strong foundation for his later contributions to immunology and infectious disease research.
Research Interests 🔬
TB Biomarkers: Focuses on identifying reliable biomarkers for tuberculosis diagnosis and monitoring treatment efficacy.
Non-Sputum Diagnostic Methods: Investigates blood- and saliva-based biomarkers to develop non-sputum diagnostic alternatives for TB, making diagnosis easier in low-resource settings.
Immunological Responses: Studies the immune system’s response to infectious diseases, with an emphasis on TB, HIV, and COVID-19.
Infectious Disease Immunology: Explores the interactions between pathogens and host immune responses to enhance understanding of disease progression and treatment outcomes.
TB Treatment Monitoring: Aims to develop new methods for tracking patient progress during TB treatment through biomarker discovery.
Cross-Disease Immunology: Compares immune responses across different infectious diseases, seeking common biomarkers and pathways for broader diagnostic and therapeutic applications.
Awards 🏆
Awards and Grants:
UCT CIDRI-Africa Postdoctoral Fellowship (2020-2022)
Fogarty HIV-Associated TB Training Program (2020-2022)
NRF Postdoctoral Fellowship (2021-2022)
SAMRC Doctoral Internship Scholarship (2017-2019)
NRF PhD and Masters Scholarships
Publications Top Notes 📚
Validation and optimisation of host immunological bio-signatures for a point-of-care test for TB disease – Front. Immunol., 2021. link
Identification of novel salivary candidate protein biomarkers for tuberculosis diagnosis – Tuberculosis, 2021. link
Protocol to quantify and phenotype SARS-CoV-2 specific T-cell response – Star Protocols, 2022. link
Blood and site of disease inflammatory profiles in HIV-1-infected pericardial tuberculosis patients – OFID, 2023. link
Application of cerebrospinal fluid host protein biosignatures in the diagnosis of tuberculous meningitis in children – Mediators of Inflammation, 2019. link